Introduction
Ocular drug delivery to the back of the eye have been widely investigated to treat eye diseases such as macular edema, diabetic retinopathy and age-related macular degeneration [1] [2] [3] [4] . Although various therapeutics have been developed and shown to be effective, they are generally not targeted to their sites of action, e.g., the macula [5] [6] [7] , which may limit their safety and efficacy. Systemic oral or parenteral administration delivers drug throughout the body with high risk of side effects. Ocular drug delivery by topical eye drops, subconjunctival injection, and intravitreal injection, more effectively target the eye, but do not specifically target the macula or other target sites within the eye. Intravitreal injection has become increasingly popular for drug delivery to the posterior segment [1, 8] . However, this method not only exposes the whole posterior segment to drug without targeting specific sites of action typically around the posterior pole, but also delivers drug to more anterior tissues, such as the ciliary body, lens and cornea. Thus, new ocular drug delivery methods are needed to target the choroid/ retina within the macula and/or near the optic disc is essential, which can increase drug efficacy and reduce side effects.
Injection into the suprachoroidal space (SCS) has been studied as a means to better target drug delivery specifically to the choroid and retina [1, 9, 10] . The SCS is a potential space between the choroid and sclera. Injection into this space allows drug to flow circumferentially at the choroid-sclera interface typically from an anterior injection site near the limbus and flowing posteriorly toward the posterior pole. While delivery can be targeted to the SCS using hypodermic needles, catheters and other devices often requiring surgical procedures performed under monitored anesthesia [11] [12] [13] [14] [15] , the most progress in the field has been made by SCS injection using a hollow microneedle [16] [17] [18] [19] .
Microneedles for SCS delivery have been designed with a length similar to scleral thickness (e.g., < 1 mm), so that perpendicular insertion into the sclera positions the needle tip at the sclera-choroid junction with direct access the SCS in a minimally invasive way [7, 17, 18, 20] . From the SCS, drugs can access sites of action such as macula and optic disc at high concentration and without obstructing the visual axis, which can be caused by injecting material intravitreally, thereby targeting delivery to reduce side effects and enhance bioavailability [11, 12, [21] [22] [23] [24] [25] . SCS injection with a microneedle has been studied in human subjects with excellent safety and tolerability in several clinical trials. Specifically, triamcinolone acetonide has been injected as a monotherapy into the SCS in patients with macular edema associated with non-infectious uveitis [26] currently in a Phase III clinical trial [27] and has been administered in combination with intravitreal injection of an anti-VEGF drug (aflibercept) in patients with retinal vein occlusion, currently in a Phase III clinical trial [28] and in patients with diabetic macular edema, currently in a phase I/II clinical trials [29] . While drug delivery via the SCS has promise, more work is needed to fully understand its strengths and weaknesses.
While SCS injection targets drug delivery to choroid and retina, it does not specifically target the posterior pole, e.g., macula [17] [18] [19] 30, 31] . Moreover, typical SCS injection volumes (e.g., ≤100 μL in the rabbit eye) are insufficient to flow injected drugs around the macula or optic disk [32] [33] [34] . Thus, greater targeting efficiency within the SCS could provide still better safety and efficacy, which is a current limitation of SCS injection.
To advance drug targeting to posterior SCS, a previous study introduced a gravity-mediated drug delivery method where high-density particle-stabilized emulsion droplets were designed to deliver drugs to the back of the eye via the SCS using gravity [19] . Drug formulations with hyaluronic acid were also developed, which spread throughout up to 100% of the SCS by a slow process after injection [30] . To target the anterior portion of the SCS, another study increased viscosity of the drug formulation using carboxymethyl cellulose to localize drugs near the ciliary body to treat glaucoma [34] .
Another method of drug delivery to the eye involves iontophoresis, which can be used for posterior segment delivery [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] . In this noninvasive method, electric current is applied at the conjunctiva to transfer charged molecules into ocular tissues mediated by repulsive and attractive forces between charged molecules and electrodes [45] [46] [47] . However, due to the ocular tissue barriers, iontophoresis is not well suited to deliver macromolecules and particles into the eye, which limits application of this technique more broadly [1, 23, [48] [49] [50] .
Guided by prior work with SCS injection and iontophoresis, we hypothesize that iontophoresis within the SCS can be designed to drive and localize charged drugs to the posterior pole, thereby leveraging the combined targeting abilities of iontophoresis and SCS delivery. Since iontophoresis is carried out by ion transfer to the counter electrode as well as the electrical repulsive force of particles, this approach should enable charged drugs to be delivered to the posterior SCS. In addition, highly controlled targeting within the SCS may be possible, by combining the targeting abilities of SCS injection and iontophoresis with high bioavailability at the posterior or anterior segment of SCS. Drug formulations including macromolecules and micro/nanoparticles, which are generally difficult to be delivered by iontophoresis only into the eye, may be delivered by SCS injection, because drugs are injected directly into the SCS by a microneedle without needing to cross epithelial barriers on cornea or conjunctiva. Moreover, since drugs can be delivered into the SCS without penetrating dense ocular layers, delivery to the posterior area by iontophoresis should be faster and more efficient than conventional iontophoresis, even using relatively a small electric current or voltage. Because iontophoresis and SCS injection have not been combined before, studying drug delivery as well as safety will be important.
Thus, herein, we developed a novel drug delivery system combining SCS injection using a microneedle and iontophoresis in the SCS to test our hypothesis. More specifically, we tested the ability of this approach to target drugs preferentially to sites of action near the posterior pole. In this drug delivery system, a customized Ag/AgCl electrode (for iontophoresis) was embedded into a syringe attached to a microneedle. We used this drug delivery system ex vivo and in vivo to provide a first assessment of delivery and safety of this iontophoretic SCS injection system.
Experimental section

Device for SCS injection and iontophoresis
For SCS injection, a 1 mL Luer-lock plastic syringe (BD Bioscience, San Jose, CA) was connected to a 30-gauge hollow microneedle measuring 750 μm in length (kindly donated by Clearside Biomedical, Alpharetta, GA) (Fig. 1b) . To apply iontophoresis within the SCS, the syringe was modified to contain a disk-type Ag/AgCl electrode with 4 mm diameter and 1 mm thickness (In vivo Metrics, Healdsburg, CA) inside the syringe barrel mounted on the distal end of the syringe plunger (Fig. 1c) . A small hole was punctured into the plunger using a gimlet, through which the lead wire from the electrode was fed. The lead wire from this electrode was connected to a power supply (6614C; Agilent Technologies, Santa Clara, CA) to control the electric current. The electric circuit was completed by connecting the power supply to another Ag/AgCl electrode, which was clipped to the rabbit optic nerve (ex vivo, Fig. 1b ) or ear (in vivo).
To manage heat and current transfer during iontophoresis,~500 μL electrolyte gel (Signa gel, Parker Laboratory, Fairfield, NJ) housed in a holder made from polymethyl methacrylate was put around the microneedle (Fig. 1d) . The holder measured 8 mm diameter and 6 mm width, and was designed in AutoCAD (Autodesk, San Rafael, CA) and Fig. 1 . Drug delivery targeted by iontophoresis in the suprachoroidal space (SCS) of the eye. a) Schematic illustration of iontophoretic targeting of ocular drug delivery via the SCS. Targeting (i) the space between sclera and choroid (ii) opens the SCS to fill it with injected drug formulation, after which (iii) iontophoresis is used to move charged species within the SCS. b) The device for SCS injection and iontophoresis comprises a syringe containing an electrode for iontophoresis and a microneedle for injection. The counter electrode is attached to the optic nerve of a rabbit eye ex vivo. c) The electrode in the syringe is mounted on the distal end of the syringe plunger. d) A holder with electrolyte gel can be added to provide increased electrical conductivity that improves electrical connectivity between the microneedle device and ocular tissue and to provide increased thermal conductivity to protect ocular tissue by conducting heat away from the microneedle and tissue. fabricated using a CO 2 laser cutter (VLS3.5, Universal laser system, Scottsdale, AZ).
Ex vivo injection procedure
Frozen whole New Zealand White rabbit eyes with optic nerve intact (Pel-Freeze, Rogers, AR) were defrosted in a water bath at room temperature (~23°C) for 30 min, and muscles, conjunctiva, and fat around the eyes were removed. To adjust intraocular pressure (IOP) to 10-15 mm Hg, Hank's Balanced Salt Solution (HBSS, Mediatech, Manassas, VA) was injected through the inferior sclera into the vitreous, and no leakage was confirmed after the injection. IOP was measured using a tonometer (iCare Tonovet, Helsinki, Finland).
As a model drug formulation, negatively charged red-fluorescent polystyrene nanoparticles with 20 nm diameter (FluoSpheres™, λ ex = 580 nm/λ em = 605 nm, ζ zeta = −50.9 mV, Life Technologies, Carlsbad, CA) at a concentration of 0.2% w/v in HBSS were filled in the microneedle syringe. The microneedle was inserted perpendicularly into the sclera 3 mm posterior to the limbus at the supranasal position of the ocular globe and 50, 100, or 200 μL of drug formulation was injected into the SCS. Iontophoresis was applied immediately after injection with the microneedle in place for 1.5, 3, or 5 min at a current of 0, 0.07, 0.14, or 0.7 mA. The counter electrode was attached to the optic nerve.
In vivo injection procedure
All in vivo procedures were approved by the Georgia Institute of Technology Institutional Animal Care and Use Committee. Practices complied with the ARVO statement for the Use of Animals in Ophthalmic and Vision Research. Albino New Zealand White rabbits (Charles River Breeding Laboratories, Wilmington, MA) were anesthetized by subcutaneous injection of ketamine and xylazine at a dose of 17.5 and 8.5 mg/kg, respectively. Isoflurane gas was used to prolong anesthesia during SCS injection and iontophoresis. Topical anesthesia, proparacaine (Akorn, Lake forest, IL), was applied 3 min prior to SCS injection. To facilitate injection, the eyelid was pushed back and fixed using a latex band. A 100 μL volume of nanoparticle formulation was injected within 3 s into the SCS at a location 3 mm posterior to the limbus at the supranasal location of the ocular globe. Then, iontophoresis was applied at 0.14 mA for 3 min with the microneedle in place and the counter electrode attached to the ear ( Fig. S1 in Supplementary material).
After iontophoresis, rabbits received an injection of 0.03 mg/kg buprenorphine to reduce the pain after the injection and were monitored for adverse effects for 1 h and then daily for one week. At least three rabbit eyes were used each experimental condition. At the end of the experiment, rabbits were euthanized under the anesthesia with an injection of 150 mg/kg pentobarbital through the ear vein. The eyes were enucleated and analyzed for nanoparticle distribution within the SCS.
Analysis of nanoparticle distribution in the SCS
To preserve the nanoparticle distribution at the end of each experiment, eyes were immediately frozen in isopropyl alcohol chilled by liquid nitrogen. The fully frozen eyes were dissected by making eight equally spaced radial cuts like flower petals from the posterior pole at the optic nerve to the limbus. The petals were splayed and flattened to expose the chorioretinal surface inside the eye. Bright field images were taken using a digital single-lens reflex camera (Cannon 60d, Melville, NY) to observe nanoparticle distribution. Fluorescence imaging was performed by illuminating the tissue with green LED light (Bluewind Multicolor RGB, HitLight, Baton Rouge, LA) and imaging with an optical bandpass filter (610 ± 10 nm; Edmunds Optics, Barrington, NJ) mounted on the camera.
To quantify nanoparticle spreading in the SCS, the tissue petals were cut to create four segments at 0-3, 3-6, 6-9, and 9-mm from the limbus.
These tissue pieces were incubated in radioimmunoprecipitation assay buffer (Abcam, Cambridge, MA) overnight and homogenized to preferentially digest the chorioretinal layer with little effect on the sclera. The supernatant in the solution was transferred to a 96-well plate and relative fluorescence of the extracted nanoparticles was measured by a plate reader (Synergy Microplate Reader, Winooski, VT). Although we did not quantify the efficiency of nanoparticle extraction from tissue, we did not observe significant residual fluorescence in tissue after extraction and all the extraction steps were the same (i.e., any inefficiency was the same in all samples). The average particle distance (APD) was calculated by finding the sum of the center distance from the limbus of each segment (e.g., the 0-3 mm segment had a center distance of 1.5 mm) weighted by the percent of nanoparticle in that segment.
Ultrasound measurement of SCS thickness
An ultrasound scanner (UBM Plus, Accutome, Malvern, PA) was used to measure SCS thickness change of the rabbit eye ex vivo. After SCS injection of 50, 100, or 200 μL HBSS at the supranasal location of the ocular globe, ultrasound B scan was performed to measure SCS thickness every minute for 10 min with at least three replicates for each volume.
Histology
Histological analysis was performed to assess safety of iontophoresis in the SCS using a microneedle. Rabbits treated with SCS injection of HBSS with the iontophoresis were monitored for 1 day or 1 week, and then euthanized. The eyes were enucleated and immediately soaked in 10% formalin solution for 12 h to fix the tissues. The fixed eyes were microtomed to~10 μm thickness and stained with hematoxylin-eosin (H&E) or periodic acid shiff (PAS). Each sample was imaged to produce cross-sectional views of the tissue around the injection site using a microscope (DP71; Olympus, Tokyo, Japan).
Statistical analysis
All data were obtained with at least three replicates, and the mean and standard deviation were calculated. One-and two-way ANOVA with replicates were used for data analysis to estimate the statistical significance of iontophoresis and volume effect. One-way ANOVA with replicates was used for the other analyses, and a p value < 0.05 was considered significant. A p value < 0.05 was marked with one asterisk (*), and < 0.01 was marked with two asterisks (**) in the graphs.
Result and discussion
Device for SCS injection and iontophoresis
We designed a device to enable targeted SCS injection combined with iontophoresis (Fig. 1) . The protocol was developed to first inject a solution of charged nanoparticles into the SCS and thereby expand its width and fill it with nanoparticles ( Fig. 1a(ii) ). While the SCS was still expanded, iontophoresis was applied with a polarity that moved the negatively charged nanoparticles toward the posterior pole (Fig. 1a  (iii) ).
The system was designed to have a continuous electrical pathway from the electrode located at the base of the syringe plunger (Fig. 1b,c) , through HBSS within the syringe and through HBSS in the SCS toward the posterior pole. Ex vivo, the counter electrode was clipped to the optic nerve to facilitate current movement posteriorly. In vivo, the counter electrode was attached to the ear, and the high electrical conductivity of HBSS in the SCS, as well as the inability of the charged nanoparticles to easily flow out of the SCS, directed delivery of nanoparticles toward the posterior pole.
A holder containing electrolyte gel was placed around the microneedle end of the syringe to reduce electrical resistance at the microneedle-tissue interface and to facilitate heat transfer away from the microneedle-tissue interface, thereby preventing excessive tissue heating during iontophoresis (Fig. 1d) .
Nanoparticle delivery in SCS by iontophoresis
We first tested the hypothesis that iontophoresis can move charged nanoparticles posteriorly in the SCS. Negatively charged fluorescent nanoparticles with 20 nm diameter were injected into the SCS of the rabbit eye ex vivo using a microneedle. Iontophoresis was then applied to drive nanoparticles toward the optic nerve. Enucleating, freezing and dissecting the eye from the posterior pole to the limbus with eight radial cuts produced a flat-mount preparation of the eye looking like flower petals (Fig. 2a, c, e) . The center of the "flower" was the site of the cornea, and each "petal" spanned from the limbus to the posterior pole. Nanoparticle distribution in the SCS was quantified by cutting each petal into four pieces and measuring fluorescence of nanoparticles extracted from each piece (Fig. 2b,d,f) .
In an eye injected with red-fluorescent nanoparticles, but without application of iontophoresis, nanoparticles were found in the SCS mostly near the limbus, with very few nanoparticles near the posterior pole (Fig. 2a(i) and b(i) ). Increasing injection volume from 50 to 200 μL increase nanoparticle delivery posteriorly, but still most particles remained in the anterior SCS (Fig. 2b(i), d(i), f(i), and Fig. S2a) .
Application of iontophoresis (0.14 mA for 3 min) increased nanoparticle delivery toward the posterior pole. After injection of 50 μL of nanoparticle suspension into the SCS, iontophoresis reduced nanoparticle concentration near the limbus (i.e., 0-3 mm in Fig. 2b ) and increased nanoparticle concentration 3-6 mm and 6-9 mm away from the limbus toward the posterior pole. However, nanoparticle delivery > 9 mm from the limbus remained just a few percent both with and without iontophoresis. Increasing injection volume to 100 and 200 μL followed by iontophoresis further increased nanoparticle spreading posteriorly such that up to 31% of nanoparticles reached the most posterior portion of the SCS (i.e., > 9 mm from the limbus) (Fig.  S2b) . Because the fluorescence images (Fig. 2a, c and e) only show the two-dimensional distribution of particles in the SCS, they mostly show the presence of particles but do not easily show concentration of particles through the SCS thickness. We therefore believe that the graphs (Fig. 2b, d and f) provide better quantitative information.
As another measure of iontophoresis driving charged nanoparticles posteriorly, the average particle distance from the limbus (i.e., APD) was determined, and was found to be significantly greater after iontophoresis (i.e., > 6 mm from the limbus) than after SCS injection alone (Fig. 2g) . Thus, application of iontophoresis and increasing SCS injection volume both increased nanoparticle delivery toward back of the eye.
Effect of iontophoresis current
To determine the effect of current intensity, iontophoresis was applied at 0, 0.14 and 0.7 mA for 3 min after SCS injection (200 μL) of nanoparticles. The nanoparticle distribution shifted more posteriorly with increasing current, which is consistent with the expected mechanism of current-driven transport of the charged nanoparticles (Fig. 3b,c) . Although iontophoresis at 0.7 mA showed the best result, the difference in posterior delivery compared to iontophoresis at 0.14 mA was relatively small.
Examination of the fluorescent micrographs may explain why (Fig. 3a) . In the absence of iontophoresis, the petals containing redfluorescent nanoparticles shown a relatively even coloring as a function of position (Fig. 3a(i) ). Iontophoresis at 0.14 mA resulted in the petals near the injection site having even coloring, but the more-distant petals showing mottled coloring (Fig. 3a(ii) ). At 0.7 mA, mottled coloring was increased in the outer petals and began to appear in the petals near the injection site as well (Fig. 3a(iii) ). These observations suggest that iontophoresis focuses nanoparticle transport from the injection site to the posterior pole with less movement to the sides and that this focusing is increased at higher current.
We interpret the mottled appearance of fluorescence in some images as evidence of nanoparticle aggregation in the SCS (see also Fig. S3 ).
Since iontophoresis is carried out by ion transfer to the counter electrode as well as the electrical repulsive force of particles, iontophoresis not only delivers the particles to the posterior direction but increases the chance of interaction among ions and particles, inducing charge non-uniformity (neutralizing particle charge). Due to the charge nonuniformity of the particles, we believe that aggregation occurred. In particular, at higher current, aggregation is increased [51] [52] [53] .
Although 0.7 mA provided better posterior delivery, we selected 0.14 mA as the preferred current in the interest of safety. High current density can cause tissue damage [35, 54] , so we opted for the lower current, which provided almost as good posterior transport.
Effect of iontophoresis application time
Since iontophoresis application time is expected to affect delivery to the posterior eye, iontophoresis was performed for different application times. As application time increased from 1.5 to 3 min, more nanoparticles were delivered posteriorly (i.e.,~30% delivered > 9 mm from the limbus, Fig. 4b ) and the average particle distance increase as well (i.e.,~6 mm from the limbus, Fig. 4c) , which was expected. However, increasing application time from 3 to 5 min did not improve posterior delivery, i.e., the percentage of nanoparticles delivered > 9 mm from the limbus was decreased (Fig. 4b ) and the average particle distance was unchanged (Fig. 4c) , which was not expected. Closer examination of the images of nanoparticle distribution in the SCS shows a mottled appearance of fluorescence (Fig. 4a) like that seen at high current (Fig. 3a) , which suggest that long application times may cause nanoparticle aggregation, which could at least partially explain the reduced effectiveness of increasing iontophoresis application time beyond 3 min.
Another possible explanation could be that the SCS rapidly collapses after injection. In previous studies, the SCS collapse time in rabbit eyes in vivo (after injection of 50 μL HBSS buffer) was reported around 40 min [55, 56] , which is much longer than the 3-5 min timeframe of iontophoresis in this study. However, the SCS of the rabbit eye ex vivo may collapse much faster than in vivo. To assess this possibility, SCS collapse time of the rabbit eye ex vivo was measured using B-scan ultrasound imaging. After SCS injection with 50, 100, and 200 μL of HBSS containing nanoparticles, SCS thickness was measured every minute for 10 min at the injection site (Fig. 5, Fig. S4 ). At all three injection volumes SCS thickness was around 1 mm immediately after injection. After 1 min, SCS thickness decreased by at least 50% (Fig. 5) . After 3 min, the SCS still appeared to be partially open (Fig. S4 ), but after 5 min, the SCS generally appeared to be completely collapsed in all three cases (Fig. 5(iii) ). This rapid collapse within 5 min may have interfered with nanoparticle movement toward the posterior pole. The observation that SCS collapse time was independent of injection volume between 50 and 200 μL may be explained by the larger area of spread in the SCS thickness at higher injection volume [56] , which may enable more rapid resorption of fluid from the SCS at larger injection volume.
Effect of iontophoresis polarity
The direction of iontophoretic movement of charged particles should be determined largely by the direction of the iontophoresis. Thus, switching iontophoresis polarity should generate iontophoretic forces that keep nanoparticles at the injection site near the limbus. The data support this expectation, where iontophoresis with reversed polarity kept nanoparticles close to the site of injection and led to a nanoparticle distribution in the SCS that was more anterior than injection without iontophoresis (Fig. 6 ).
In vivo nanoparticle delivery by iontophoresis
Based on the ex vivo results, nanoparticle delivery by iontophoresis was studied in the rabbit eye in vivo using 100 μL injection of nanoparticles followed by iontophoresis at 0.14 mA for 3 min. Although increasing injection volume (up to 200 μL) increased posterior targeting, SCS injection using volumes as large as 200 μL have not been extensively studied in vivo and have uncertain safety profile. Standard SCS injections, and intravitreal injections, in humans are just 50 μL [57] . Prior studies in New Zealand white rabbits have found that injection of 50-100 μL into the SCS was well tolerated [30, 34, 58] . Thus, we chose 100 μL injection volume for in vivo experiments.
After injection without iontophoresis, nanoparticles were spread in the SCS similarly to findings after injection in the rabbit eye ex vivo (Fig. 7a(i) ). Since prior studies in New Zealand white rabbits using similar nanoparticles injected into the SCS showed that particle Fig. 4 . Effect of iontophoresis application time after injection of nanoparticles in the suprachoroidal space (SCS). Representative fluorescence micrographs (a), distribution of red-fluorescent nanoparticles in the SCS (b), average distance of nanoparticle transfer in the SCS (c) due to iontophoresis at 0.14 mA for (i) 1.5 min, (ii) 3 min, and (iii) 5 min after injection of 200 μL of nanoparticles in HBSS into the SCS of rabbit eyes ex vivo. Fluorescence micrographs (a) show representative flat mounts of the eye after dissection with radial cuts from the posterior pole to the limbus. Yellow arrows point to sites of injection into the SCS. ǂ Average particle distance (APD) (mm). Graphs (b and c) present average ± standard deviation based on 3 replicate samples. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
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Journal of Controlled Release 277 (2018) [14] [15] [16] [17] [18] [19] [20] [21] [22] fluorescence distribution was similar between 0 days and 14 days after injection, we did not assess particle distribution over time after the injection without iontophoresis [30] . Examination of images taken 1 h after iontophoresis shows petals near the injection site with fluorescent nanoparticles throughout the petals from the limbus to the posterior pole ( Fig. 7a(ii) ). Other petals located distant to the injection site show nanoparticles localized only near the posterior pole with little or no nanoparticles near the limbus (Fig. 7a(ii) ). To explain this nanoparticle distribution, it appears that nanoparticles at the posterior end of the petals were delivered from petals in the opposite side of the eye by iontophoresis around the optic nerve (Fig. S5) . This delivery pattern imaged 1 h after iontophoresis resulted iñ 30% of nanoparticles delivered > 9 mm from the limbus (Fig. 7b(ii) ), and the average position of nanoparticles~6 mm from the limbus (Fig. 7c(ii) ), in good agreement with findings ex vivo. Examination of nanoparticles in the SCS 1 week after iontophoresis showed a similar distribution (Fig. 7b(iii) ) and average distance from the limbus (Fig. 7c  (iii) ) compared to findings at 1 h.
In vivo safety analysis
The safety of iontophoresis in the SCS was assessed by clinical exam and histology. After iontophoresis, the injection site was observed with the naked eye. Tissue at the injection site appeared normal, with no evidence of tissue damage, inflammation, or burns (Fig. S6) . No adverse events were reported by the veterinarian staff caring for the rabbits at any time. Safety of the procedure may have been enhanced by iontophoresis device design. Since the electric current can generate heat around the electrode in the syringe during iontophoresis, a thermally (and electrically) conductive electrolyte gel was placed in the microneedle holder to dissipate heat from the microneedle and surrounding tissue.
Histological analysis was performed to further examine effects of iontophoresis on tissue around the injection site (Fig. S7) . Tissue was collected one day after iontophoresis from three different rabbits. Tissue from one rabbit eye appeared normal (Fig. S7b(i) ). However, evidence of mild choroidal inflammation was seen in the second rabbit ( Fig. S7b(ii) ) and minor chorioretinal "scarring" was seen in the third rabbit ( Fig. S7b(iii) ) near the site of injection. We do not have histology from eyes that received SCS injection without iontophoresis, so we do not know the role of SCS injection versus iontophoresis in generating these effects. However, prior studies have not usually shown tissue damage from SCS injection [16, 34, 59 ], so we believe that iontophoresis is more likely the cause. One week after iontophoresis, eyes from three additional rabbits were examined histologically and all three appeared normal (Fig. S7c) . This indicates that although iontophoresis in the SCS may generate minor tissue damage at the site of injection, the tissue can recover within 1 week. The effects of repeated injection, which may be needed to treat chronic diseases was not assessed here and will require future studies. However, these findings are based on limited data collected at just one iontophoresis condition in rabbits. Thus, safety issues should be further studied and optimized by possible modification of electrode design, iontophoresis conditions and other factors.
Study limitations
The experimental set-ups in the ex vivo and in vivo studies were different, making direct comparisons difficult. We used the ex vivo setup to study the effects of iontophoretic parameters on nanoparticle delivery in the SCS. While these ex vivo findings will not translate directly to the in vivo environment, we believe that the principles shown in the ex vivo study can nonetheless be used to guide and interpret findings in vivo. Thus, we optimized iontophoresis parameters ex vivo to guide the parameters used in this first study of SCS iontophoresis in vivo.
The microneedle injection method and microneedle electrode were used in the same way in the ex vivo and in vivo studies. Previous iontophoresis studies in vivo (using New Zealand white rabbits) attached the counter electrode to the rabbit ear for drug delivery to the back of the eye [36, 60] . However, since there is no ear in the ex vivo study, we attached the counter electrode to the optic nerve instead.
While transport of nanoparticles in the SCS by iontophoresis can be more easily studied ex vivo, understanding safety concerns requires in vivo study. In ex vivo experiments, we looked for direct effects of iontophoresis on tissue structures, but issues of cell death, inflammation and other responses were only considered in vivo. The gross observation and histological analysis performed in this study in vivo provides an initial assessment of safety, but additional studies are needed, especially to assess long-term effects and the effects of possible repeated administration to treat chronic conditions.
In principle, charged drugs can be delivered by iontophoresis regardless of negative or positive charge by adjusting the electric field polarity. However, drug -tissue interactions may be influenced by charge, where positively charged drugs may more likely bind to negatively charged tissue [2, 61, 62] . Delivery of DNA, RNA and other highly charged compounds would be most suitable for delivery using iontophoresis. In contrast, weakly charged drugs (e.g. bevacizumab and ranibizumab) may be delivered less efficiently by iontophoresis. However, this limitation can be addressed by drug formulation modification, such as conjugation with highly charged polymer or encapsulation in charged particles or liposomes, to generate strong charge around the drug. Future studies will be needed to build off this initial study of iontophoresis in the SCS and more fully assess its strengths and weaknesses.
Conclusion
In this study, iontophoresis in the SCS using a microneedle for targeted drug delivery in the eye was studied for the first time. We first designed a device comprised of a hollow microneedle attached to a syringe to enable targeted injection into the SCS, an electrode embedded to the syringe to administer iontophoresis into the SCS (in combination with a counter-electrode attached to the optic nerve ex vivo or to the rabbit ear in vivo), and a holder containing electrolyte gel placed around the microneedle to increase electrical and thermal conductivity at the microneedle-tissue interface.
When charged nanoparticles were injected into the SCS, the application of iontophoresis increased the transport of nanoparticles posteriorly toward the posterior pole. Increasing injection volume (between 50 and 200 μL) increased posterior targeting of nanoparticle delivery. Increasing iontophoresis current from 0.14 to 0.7 mA led to a small increase in posterior targeting, but concern about possible tissue damage from the higher current led us to prefer the lower current as a safer option. Increasing iontophoresis application time from 1.5 to 3 min increased posterior targeting, but further increasing to 5 min did not help. Ultrasound imaging showed that the SCS of the rabbit eye ex vivo collapsed within~5 min, which may explain why additional nanoparticle transport did not occur between 3 and 5 min.
Based on the findings from ex vivo studies, we carried out SCS iontophoresis in the rabbit eye in vivo using 100 μL injection of nanoparticles followed by iontophoresis at 0.14 mA for 3 min. At these conditions, approximately 30% of charged nanoparticles were localized in the most posterior region of the SCS (> 9 mm from the limbus) and the average nanoparticle distance from the SCS was approximately 6 mm. These findings are in good agreement with ex vivo data. Iontophoresis in the SCS was generally well tolerated, with only mild, transient tissue effects at the site of injection.
We conclude that iontophoresis can increase posterior targeting of charged nanoparticles in the SCS after injection using a microneedle. Future treatment of ocular indications, especially those located toward the posterior pole, could benefit from ocular drug delivery targeted by iontophoresis in the SCS.
